The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...

The gene therapy Casgevy, which will now be offered to some patients in England, could help people live disease-free, experts ...

The UK has approximately 17,500 individuals living with sickle cell disease, a condition particularly prevalent amongst those ...

However, instead of directly editing a faulty gene, Casgevy instead takes advantage of a process that happens when babies are in the womb, where they make red blood cells with foetal haemoglobin ...

However, significant barriers stand in the way of realising this promise on a worldwide scale, from manufacturing costs and ...

The growing use of AI has opened new avenues for healthcare marketers, revolutionising how they approach new initiatives.

One of the world’s most expensive medicines will be used to treat some patients with sickle cell disease in England using the state-funded National Health Service.Most Read from BloombergHow the 2025 ...

Casgevy, also known as exa-cel, was the first treatment to be licensed using the gene-editing tool Crispr, which earned its inventors the Nobel Prize for chemistry in 2020. The process involves ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...